Heima vs Mira — how do they compare? Heima trades at Rp2,469 (market cap Rp204,92M, Rp1,1T 24h volume), while Mira trades at Rp700.16 (market cap Rp226,43M, Rp101,47M 24h volume). The key difference: Heima and Mira are close in size by market cap, and Heima's circulating supply is 81,5M / 100M HEI (82%) versus 321,5M / 1B MIRA (33%) for Mira. Which is the better fit depends on your goals — on Pluang, investors hold Heima for 11 Days and Mira for 22 Days on average.
| HEI | MIRA | |
|---|---|---|
Market Cap | Rp204,92M | Rp226,43M |
Volume (24h) | Rp1,1T | Rp101,47M |
Circulating Supply | 81,5M / 100M HEI (82%) | 321,5M / 1B MIRA (33%) |
Typical Hold Time | 11 Days | 22 Days |
Signals from Pluang's Aura AI — not financial advice
HEI (Heima) is currently trading at Rp2,198.904 with a market cap of Rp179.25 million, showing bullish technical signals despite mixed moving averages. The token has a circulating supply of 81.5 million HEI (82% of max supply) with an average hold time of 11 days. Technical indicators show strong momentum with RSI_6 at 21.06 (oversold) and ADX readings above 66 indicating strong trend strength. Support levels are established at Rp1,831 (S3) to Rp2,087 (S1), with resistance at Rp2,343 (R1) to Rp2,600 (R3).
Overall outlook is cautiously optimistic with bullish oscillators supporting upward momentum, though bearish moving averages suggest near-term consolidation. Key opportunities include potential breakout above Rp2,241 pivot point, while risks include low liquidity and typical crypto volatility. Investors should monitor volume patterns and network adoption metrics for confirmation of sustained momentum.
MIRA token trades at Rp724 with bearish technical signals as moving averages indicate strong selling pressure. The token shows neutral oscillators but faces resistance at Rp726-758 levels. With 33% circulating supply and 22-day average hold time, market participation remains limited. Recent ecosystem developments show progress in pharmaceutical research applications, though direct token utility updates are scarce.
Overall outlook remains cautious due to technical bearishness and limited trading volume. Key opportunity lies in potential protocol adoption from pharmaceutical research partnerships. Major risks include low liquidity, high volatility, and regulatory uncertainty surrounding crypto-pharma intersections. Investors should monitor exchange listings and token utility expansion.
What Pluang investors did over the last 30 days
As an evolution of the Litentry Network, the Heima Network was developed focusing on decentralized identity and privacy solutions. Building on this foundation, Heima expanded its scope to address cross-chain asset management and multi-chain interoperability.
Read more on HEI →Mira is a decentralized verification network that enables autonomous AI by eliminating human oversight. Using consensus-based verification across multiple AI models, Mira delivers mathematically verifiable and trustless results in real time. This ensures accuracy and reliability for critical fields like healthcare, finance, and law—transforming AI from a supervised tool into truly independent intelligence.
Read more on MIRA →